ABT Trading Analysis - 10/21/2026 12:31 PM — TRU-SENTIMENT

News Headlines & Context

The following items are provided from general knowledge and are separated from the data-driven analysis below:

• Abbott Laboratories (ABT) recently reported Q3 2026 earnings showing steady medical device growth but softer nutrition segment sales; shares dipped post-report.
• ABT announced expansion of its continuous glucose monitoring manufacturing capacity ahead of holiday demand season.
• Regulatory headlines around Medicare reimbursement rates for diabetes care could impact ABT's diagnostics margin outlook into 2027.
• The company went ex-dividend on 2026-10-15 with a $2.52 annual rate, a routine catalyst that may have contributed to near-term price softness.
• Broad healthcare sector rotation out of defensives earlier in October may relate to ABT's slide from mid-$105 to sub-$100 levels seen in the embedded data.

Context: These headlines suggest fundamental stability but mixed segment momentum. The ex-dividend date and sector rotation align with the price decline observed in the daily and minute bar data, while the options sentiment being balanced reflects uncertainty around near-term catalysts.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for ABT:

• Trailing P/E is 33.20 with trailing EPS of $3.14; no forward P/E, PEG, or price-to-book provided (all null).
• Dividend yield is 2.42% with a $2.52 rate and ex-dividend date of 2026-10-15.
• Market cap is $170,321,598,690.00 with 1,730,383,000 shares outstanding.
• Beta is 0.34 (low volatility relative to market); 52-week range is $81.97 to $132.03.
• Institutional ownership is 58.71%; average volume is 9,310,000 shares.
• Historical volatility is 20.34%; fiscal year end was 2025-12-01.
• No revenue growth, profit margins, ROE, debt-to-equity, or free cash flow data provided (all null).
• No analyst consensus or target mean price provided (null).

Fundamentals show a large-cap defensive profile with low beta and consistent dividend. The trailing P/E of 33.20 is elevated versus typical peer med-tech averages, but absent PEG or margin data, valuation cannot be fully benchmarked. The low beta and institutional base contrast with the recent sharp price drop to $98.47 (minute bars), indicating the technical weakness is not explained by provided fundamental deterioration.

Current Market Position

From the embedded data, the daily close on 2026-10-20 was $102.76 with intraday low of $100.75 and high of $105.62. Minute bars show 2026-10-20 opened at $105.53 and declined to $102.76; by 2026-10-21 12:00 the last bar closed at $98.47 after trading as low as $97.80. Recent price action shows a clear downleg from the $105 area to sub-$99.

Key observational levels from data: 30-day range high $106.86, low $95.06; Bollinger lower band $96.22; daily low 2026-10-20 at $100.75; minute low 2026-10-21 at $97.80. Resistance is seen near $104.65 (2026-10-15 close) and $105.68 (SMA-50).

Intraday momentum on minute bars is weak but stabilizing: from 11:40 at $97.90 to 12:00 at $98.47, a mild bounce with declining volume (188,994 to 135,815).

Technical Analysis

SMA alignment: Price ($102.76) is below SMA-5 ($103.82) and SMA-50 ($105.68) but above SMA-20 ($100.98). No golden/death cross imminent; SMA-5 below SMA-50 indicates intermediate-term bearish bias. RSI at 61.94 shows neutral-to-moderate momentum, not overbought. MACD (-0.11) below signal (-0.09) with negative histogram (-0.02) confirms mild bearish momentum. Bollinger Bands: price is between middle ($100.98) and lower ($96.22), no squeeze. Price sits in lower-middle of 30-day range (95.06-106.86), approx 35% up from low.

True Sentiment Analysis (Delta 40-60 Options)

Options flow (Delta 40-60 only) for 2026-10-21 shows:

Call Dollar Volume: $432,285.00 (56.70%) Put Dollar Volume: $330,460.00 (43.30%) Total: $762,745.00

Sentiment is classified as Balanced. Call contracts 1,423 vs put 958; call trades 32 vs put 25. Pure directional conviction is slightly call-leaning but not decisive. The balanced read suggests no strong near-term directional expectation, which diverges from the bearish daily price slide to $98.47 (minute bars). This divergence implies the drop may be mechanical (ex-dividend, sector) rather than conviction-driven shorts.

Key Price Levels (Observational Only)